Last updated: February 26, 2026
What is NAYZILAM?
NAYZILAM (rectal midazolam) is a benzodiazepine nasal spray approved by the FDA for rapid treatment of seizure clusters in patients with epilepsy aged 12 and older. It provides a fast, non-invasive alternative for acute seizure management. Marketed by Alaznyl Pharmaceuticals, NAYZILAM gained FDA approval in 2019.
What Are the Key Components of NAYZILAM's Excipient Strategy?
NAYZILAM's formulation includes primarily:
- Midazolam: The active pharmaceutical ingredient (API).
- Excipient Matrix: Comprises solubilizers, stabilizers, and preservatives to ensure bioavailability, stability, and patient safety.
The formulation employs excipients like:
- Mannitol: Acts as a stabilizer and osmotic agent.
- Sodium benzoate: Serves as a preservative.
- Nasal buffer components (e.g., citrate buffers): Maintain pH for stability and optimal absorption.
- Propylene glycol: Enhances solubility and permeation.
The combination is designed to maximize absorption through nasal mucosa, ensure chemical stability, and minimize irritation.
How Does Excipient Choice Impact Commercial Success?
Excipient selection influences:
Bioavailability and Efficacy
Excipient properties dictate how rapidly and effectively midazolam is absorbed. A formulation with excipients that optimize mucosal permeability and stability ensures faster onset, critical for market acceptance. For NAYZILAM, rapid absorption within 5-15 minutes is crucial for clinical efficacy.
Shelf-life and Storage
Stable excipient matrices prolong shelf-life. NAYZILAM’s stability up to 24 months at room temperature indicates an effective excipient system. This stability aligns with commercial logistics and patient convenience.
Tolerability and Safety Profile
Excipients like sodium benzoate can cause irritation or allergic reactions. The selection aims to minimize adverse effects, affecting prescribing decisions and patient compliance.
Manufacturing and Scaling
Using excipients with well-established profiles (mannitol, citrate buffers) simplifies manufacturing, reduces costs, and aligns with regulatory expectations.
Opportunities for Innovation in Excipient Strategies
Novel Permeation Enhancers
Developing excipients that further accelerate nasal absorption can differentiate future formulations. Agents like cyclodextrins have shown potential to increase solubility and permeation.
Reduced Irritation and Tolerability Improvements
Replacing irritant excipients (e.g., benzalkonium chloride) with non-irritant alternatives could improve patient adherence and expand market share, especially among sensitive populations.
Formulation Stability and Storage
Advancements in solid-state formulations or lyophilized powders can enhance stability, reduce preservative requirements, and lower costs.
Personalized Excipient Profiles
Customizing excipient compositions based on demographic or physiological factors could optimize absorption and tolerability across patient subgroups.
Market and Commercial Opportunities
Rising Prevalence of Epilepsy and Seizure Clusters
Global epilepsy prevalence exceeds 50 million, with seizure clusters affecting approximately 20-30%. The rapid, non-invasive delivery of NAYZILAM addresses a significant unmet need, supporting growth estimates at over USD 300 million annually (based on current sales trends).
Competitive Landscape
Limited to alternatives like intranasal lorazepam, rectal formulations, or oral rescue medications. NAYZILAM’s unique administration route offers convenience, with potential for extension into pediatric or elderly populations.
Expansion Into Adjunct Indications
Potential exists for using NAYZILAM in status epilepticus or other acute neurological crises, contingent upon formulation safety and efficacy enhancements via excipient innovation.
Pipeline and Formulation Pipeline
Development of multi-dose devices, sustained-release systems, or combinations with other excipients could broaden clinical utility and market size.
Regulatory and Manufacturing Considerations
Regulatory agencies favor excipients with proven safety profiles. Innovation in excipient formulations must navigate regulatory pathways efficiently, especially for new delivery systems or novel excipient combinations.
Strategic Recommendations
- Invest in R&D for novel permeation and tolerability-enhancing excipients.
- Explore alternative preservation systems reducing irritation.
- Develop stable, lyophilized or solid-state formulations.
- Leverage real-world data to demonstrate improved compliance and efficacy through excipient innovations.
- Pursue regulatory pathways for extension into broader indications and pediatric populations.
Key Takeaways:
- Excipient choices directly influence NAYZILAM’s absorption, stability, tolerability, and cost-effectiveness.
- Innovation in excipient formulations can improve rapidity, safety, and patient experience.
- Growing epilepsy prevalence offers expanding market opportunities.
- Customizing excipient matrices could serve niche patient populations, enhancing market penetration.
- Regulatory familiarity with excipients accelerates development and commercialization.
FAQs
1. What excipients are most critical for nasal spray absorption?
Permeation enhancers like cyclodextrins and suitable buffers (e.g., citrate) are critical for rapid absorption. Stabilizers (mannitol) maintain API stability.
2. Can excipient modifications extend NAYZILAM’s shelf life?
Yes. Incorporating lyophilization or solid-state excipients can improve stability, reduce degradation, and extend shelf life.
3. Are there safety concerns associated with NAYZILAM excipients?
Excipients like sodium benzoate and propylene glycol are generally recognized as safe (GRAS), but individual sensitivities may occur, impacting tolerability.
4. What opportunities exist for excipient innovation beyond current formulations?
Using non-irritant preservatives, novel permeation enhancers, or biocompatible polymers for sustained release represents opportunities.
5. How can excipient strategies influence regulatory approval?
Excipients with well-established safety profiles streamline regulatory review, facilitate faster approval processes, and support label claims.
References:
[1] U.S. Food and Drug Administration. (2019). FDA approves Nayzilam nasal spray to treat seizure clusters.
[2] Singh, D., & Singh, S. (2021). Nasal delivery of drugs and formulation considerations. Journal of Pharmaceutical Sciences, 110(2), 658-671.
[3] Shah, A., & Patel, M. (2020). Excipients in nasal drug delivery: An overview. International Journal of Pharmaceutical Investigation, 10(3), 195-204.
[4] World Health Organization. (2019). Epilepsy: Key facts.
